ORPHA:231466
Acute sensory ataxic neuropathy
Also known as: ASAN · Acute sensory ataxic GBS · Acute sensory ataxic Guillain-Barré syndrome
Publications
142
60.6th percentile
Trials
0
Interventional, condition-specific
Researchers
792
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare variant of Guillain-Barré syndrome characterized by acute onset monophasic sensory with diminished or absent tendon reflexes, loss of proprioception, positive Romberg sign and nerve conduction features of demyelination. It presents several weeks after acute infection with paresthesias, and neuropathic pain.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016500
- UMLS:C4707661
Additional Mondo synonyms (3)
acute sensory ataxic GBS · acute sensory ataxic Guillain-Barre syndrome · acute sensory ataxic Guillain-Barré syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
142 matched papers (72 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
142
142 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
142 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
72 in the last 10 years · medium confidence · 60.6th percentile (publications denominator)
Phrase hits: 142 · MeSH hits: 0
Who's working on it?
792
Distinct author names in 142 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01
- 02Gallardo E4 papers · 2019
Service of Radiology, University Hospital "Marqués de Valdecilla (IDIVAL)", University of Cantabria, and "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)", Santander, Spain.
Papers in Europe PMC - 03Uncini A4 papers · 2014
Neurocenter of Southern Switzerland, Ospedale Civico, Via Tesserete 46, CH-6900 Lugano, Switzerland. uncini@unich.it
Papers in Europe PMC - 04Illa I3 papers · 2012
Department of Neurology, Institut de Recerca, Hospital Sta Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain. illa@santpau.es
Papers in Europe PMC - 05Koga M3 papers · 2002Papers in Europe PMC
- 06Liu Y3 papers · 2025
Department of Neurology, Xijing Hospital, The Air Force Medical University, Xi'an, People's Republic of China.
Papers in Europe PMC - 07Susuki K3 papers · 2013
Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA. susuki@bcm.edu
Papers in Europe PMC - 08Willison HJ3 papers · 2017
Neuroimmunology Group, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
Papers in Europe PMC - 09Albers JW2 papers · 2014
Department of Neurology, University of Michigan, 1C325/0032 University Hospital, 1500 E. Medical Center Drive, Box 0316, Ann Arbor, USA, MI 48109-0032.
Papers in Europe PMC - 10Baba M2 papers · 2001
Department of Neurology, Institute of Neurological Diseases, Hirosaki 036, JapanDepartment of Medicine III, Hirosaki University School of Medicine, Hirosaki 036, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acute sensory ataxic neuropathy" OR "Acute sensory ataxic GBS" OR "Acute sensory ataxic Guillain-Barré syndrome" OR "acute sensory ataxic Guillain-Barre syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acute sensory ataxic neuropathy" OR "Acute sensory ataxic GBS" OR "Acute sensory ataxic Guillain-Barré syndrome" OR "acute sensory ataxic Guillain-Barre syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ASAN
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:17:46.740Z